Healthcare News | BioTuesdays by Kilmer Lucas IR

Developments

PharmAust achieves successful Phase 2 cancer study in pet dogs

PharmAust (ASX:PAA) achieved a successful outcome in a Phase 2 trial investigating the anti-cancer effects of its monepantel tablets in dogs with treatment naïve B-cell lymphoma. Following 14 days of monepantel tablet...

May 12, 2020

Developments

Imagin Medical supports Bladder Cancer Awareness Month

This month, Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) will be undertaking a number of efforts and activities to help raise awareness about bladder cancer. Imagin has created and will...

May 12, 2020

Markets

SVB Leerink slashes Genfit PT to $20 from $50

SVB Leerink slashed its price target for Genfit (NASDAQ:GNFT) to $20 from $50, but maintained its “outperform” rating, citing topline interim Phase 3 results that showed elafibranor failed to demonstrate a statistically...

May 12, 2020

Markets

HCW halves Aimmune Therapeutics PT to $15 from $30

H.C. Wainwright halved its price target for Aimmune Therapeutics (NASDAQ:AIMT) to $30 from $15, and reiterated its “neutral” rating, citing the pandemic’s impact on the launch of Palforzia, the first drug treatment of...

May 12, 2020

Markets

BTIG cuts Endologix to neutral; removes price target

BTIG downgraded Endologix (NASDAQ:ELGX) to “neutral” without a price target, citing “greater uncertainty” that the potential COVID-19 impact on revenue could put the company’s financial covenants in peril. The stock...

May 12, 2020

Markets

Analysts upgrade CymaBay Therapeutics and raise PTs

Analysts for Stifel, SVB Leerink and Roth Capital Partners upgraded CymaBay Therapeutics (NASDAQ:CBAY) and raised their price targets, citing a unanimous vote by an independent review that recommend further development...

May 12, 2020

Markets

HCW ups Pulse Biosciences PT to $16 from $6

H.C. Wainwright raised its price target for Pulse Biosciences (NASDAQ:PLSE) to $16 from $6, citing the company’s agreement with the FDA on requirements for a 510(k) submission for a general dermatological indication of...

May 12, 2020

Developments

Kane Biotech posts positive results from anti-biofilm shampoo consumer product test

Kane Biotech (TSX-V:KNE) reported positive results from its consumer product test evaluating the efficacy of its new shampoo on dermatitis and dandruff. The shampoo was developed based on research indicating that...

May 12, 2020

Markets

Brookline doubles Arcturus Therapeutics PT to $64 from $32

Brookline Capital Markets raised its price target for Arcturus Therapeutics (NASDAQ:ARCT) to $64 from $32, citing positive immunogenicity data for its COVID-19 vaccine. The stock was quoted at $44.88, up $5.65, in...

May 11, 2020

Developments

Kiniksa Pharma updates data from COVID-19, chronic pruritis studies

Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported updated data from its open-label study of mavrilimab for the treatment of COVID-19-related pneumonia, as well as its Phase 2 trial for vixarelimab for the treatment of...

May 11, 2020

Developments

Strongbridge Biopharma completes enrollment in Phase 3 Cushing’s syndrome trial

Strongbridge Biopharma (NASDAQ:SBBP) completed enrollment in its Phase 3 trial of RECORLEV for the treatment of endogenous Cushing’s syndrome, an endocrine disease caused by chronic elevated cortisol exposure. A...

May 11, 2020

Developments

FDA clears Pluristem IND for PLX-PAD in COVID-19-related ARDS

Pluristem Therapeutics (NASDAQ:PSTI) received FDA clearance for an IND application to treat patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 with intramuscular injections of PLX-PAD. ...

May 8, 2020

PharmAust achieves successful Phase 2 cancer study in pet dogs

Imagin Medical supports Bladder Cancer Awareness Month

SVB Leerink slashes Genfit PT to $20 from $50

HCW halves Aimmune Therapeutics PT to $15 from $30

BTIG cuts Endologix to neutral; removes price target

Analysts upgrade CymaBay Therapeutics and raise PTs

HCW ups Pulse Biosciences PT to $16 from $6

Kane Biotech posts positive results from anti-biofilm shampoo consumer product test

Brookline doubles Arcturus Therapeutics PT to $64 from $32

Kiniksa Pharma updates data from COVID-19, chronic pruritis studies

Strongbridge Biopharma completes enrollment in Phase 3 Cushing’s syndrome trial

FDA clears Pluristem IND for PLX-PAD in COVID-19-related ARDS

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter